Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
Date:10/23/2008

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) today announced that an abstract entitled "Phase I Trial of Oncolytic Reovirus (REOLYSIN(R)) in Combination with Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers" will be available in the November/December issue of the Journal of Immunotherapy, the official journal of the International Society for Biological Therapy of Cancer (iSBTc). The principal investigator for the trial is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The abstract covers results of the trial (REO 011) up to July 2008. At that time, 11 patients had received 46 cycles of treatment, with no dose-limiting toxicities. Of the 10 evaluable patients, there were three patients with a partial response, five patients with stable disease and two patients with progressive disease. On the basis of promising response data in the patients with head and neck cancers, a Phase II study has been opened in head and neck cancer patients using the 3x10(10) TCID(50) dose on five consecutive days.

A poster presentation that will include current results of the trial is scheduled to be presented on November 1, 2008 at the iSBTc annual meeting. The meeting is being held in San Diego, California from October 31-November 2, 2008.

The poster should be available on the Oncolytics website at http://www.oncolyticsbiotech.com on November 3, 2008.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visi
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Myriant Corporation, a global ... a distribution agreement with Azelis Group, a specialty ... bio-succinic acid in the Nordics, Benelux, France, Iberia, ... in the industrial and base chemicals markets. , ... a far-reaching chemical portfolio with extensive distribution networks ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... Chief Executive Officer, will present at the Rodman & Renshaw ... New York on Tuesday, Sept. 9, 2014 at ... webcast of the presentation will be accessible by visiting the ... section. About Oncothyreon Oncothyreon ...
(Date:9/2/2014)... -- Spherix Incorporated (SPEX) -- an intellectual property development company committed to ... that the United States Patent & Trademark Office (USPTO) ... of August that are part of a standard essential ... are: , U.S.RE45,065 issued August 5, ... , U.S.RE45,095 issued August 26, 2014.  ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is ... $1,070.7 million in 2014, growing at a CAGR ... oligonucleotide synthesis market is categorized on the basis ... geography. The synthesized oligonucleotides segment is expected to ... synthesis market during the forecast period, owing to ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... May 2 Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO) announced ... Officer., Pulmo BioTech Chief Executive Officer Garry McCann said ... the company and that Rajiv,s,experience and financial acumen would be ... of its Phase I Human Trials and then into Phase,II., ...
... 2 eResearchTechnology, Inc.,(eRT), (Nasdaq: ERES ... collection and interpretation services,announced today that Dr. ... Executive Officer, and Richard Baron, the Company,s ... the Deutsche Bank 33rd Annual,Healthcare Conference at ...
... CLARA, Calif., May 2 Finesse Solutions, LLC,Santa ... solutions for,life sciences process applications, announced the release ... pilot and small scale production,applications. The PLSS package ... I/O capability and NEMA 4X enclosures. TruViu(TM) PLSS,consists ...
Cached Biology Technology:Pulmo BioTech Announces Appointment of Chief Financial Officer 2Pulmo BioTech Announces Appointment of Chief Financial Officer 3eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008 2Finesse Solutions Introduces the TruViu(TM) PLSS System 2
(Date:9/2/2014)... spiky legs and their propensity for eating anything, including ... And now research from North Carolina State University finds ... across the eastern United States. , "The good news ... kind of threat to humans," says Dr. Mary Jane ... author of a paper about the research. , The ...
(Date:9/1/2014)... us fat? An increasing amount of research shows an ... a more sedentary lifestyle. Now, a new Cornell University ... Some TV programs might lead people to eat twice ... you,re watching an action movie while snacking your mouth ... lead author on the new article just published in ...
(Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Can action movies make you fat? 2Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... by Johns Hopkins sensory biologists studying fruit flies, has revealed ... this same step suffer retinal dystrophies, which manifest as visual ... article, published Jan. 26 in Current Biology paves ... therapies to treat human retinal degeneration. Retinal dystrophies ...
... two languages regularly during pregnancy puts infants on the ... in Psychological Science , a journal of the ... (who spoke both languages regularly during pregnancy) exhibit different ... one language. Psychological scientists Krista Byers-Heinlein and Janet ...
... WI, February 16, 2010-Educators, especially in science and ... desire to learn in their students. Perhaps no ... Marvin Druger. A professor emeritus at Syracuse University, ... Biology. He shared his experiences teaching over 40,000 ...
Cached Biology News:All eyes on retinal degeneration 2Bilingual babies: The roots of bilingualism in newborns 2A mission statement for science educators 2
Candida (IgA) -Ab EIA Sample Size: 5 l...
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
... Whether your protein is in solution or ... using MALDI-TOF/TOF mass spectrometry. Proteins will be digested ... weights (mass) of the peptides are determined by ... top 10 peaks (peptides) from MALDI-TOF will be ...
Biology Products: